Study Points to Role of ABCB1 Gene Alterations in Plavix-Treated Patients' Cardiovascular AEs
March 17, 2010
Study Points to Role of ABCB1 Gene Alterations in Plavix-Treated Patients' Cardiovascular AEs
The study showed that alterations in the ABCB1 gene had no link to increased bleeding in patients treated with either Plavix or its competitor Effient, though patients treated with Plavix who were homozygous for a particular allele had an increased risk of cardiovascular death, heart attack, or stroke.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
April 4, 2012 / Pharmacogenomics Reporter - Medco Study to Gauge Whether PGx-Based Plavix Dosing is as Effective as Higher-Priced Effient
October 21, 2009 / Pharmacogenomics Reporter - PGx Highlights from American College of Cardiology Annual Meeting
April 4, 2012 / Pharmacogenomics Reporter - Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter - Medco to Compare Effient vs. PGx-Guided Plavix in Heart Patients on Prevacid
July 28, 2010 / Pharmacogenomics Reporter